Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
AstraZeneca PLC (AZN) - $25 value - yours FREE >>
Bristol Myers Squibb Company (BMY) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca PLC (AZN) - $25 value - yours FREE >>
Bristol Myers Squibb Company (BMY) - $25 value - yours FREE >>
Image: Bigstock
AstraZeneca's Symbicort Positive in Pediatric Asthma Study
AstraZeneca PLC (AZN - Free Report) announced phase III study results for its well-known product for asthma, Symbicort. The study showed that the drug improves lung function in pediatric asthma patients aged six to twelve years. Results from CHASE 3 phase III study evaluated Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms versus budesonide 80 micrograms, in pediatric patients.
The CHASE 3 study was conducted by the company after FDA asked for additional data on budesonide and formoterol, particularly regarding the impact of different doses, in pediatric asthma patients between six and twelve years of age.
AstraZeneca has been making significant progress with its pipeline. Promising pipeline candidates dealing with asthma include benralizumab for asthma and chronic obstructive pulmonary disease (COPD) and tralokinumab for asthma and atopic dermatitis.
AstraZeneca is working on bolstering its pipeline and is looking for suitable acquisitions and deals. In order to strengthen its respiratory portfolio, AstraZeneca acquired rights to Allergan plc’s branded respiratory business in the U.S. and Canada in Mar 2015.
In May 2016, AstraZeneca acquired Takeda Pharmaceutical Company Limited’s core respiratory business, thereby gaining global rights to Daliresp/Daxas
In Feb 2014, AstraZeneca boosted its diabetes portfolio by acquiring Bristol-Myers Squibb Company’s (BMY - Free Report) global diabetes business.
Last week the company reported its third-quarter 2016 results with core earnings of $1.32 per American Depositary Share, comfortably beating the Zacks Consensus Estimate of 48 cents.
ASTRAZENECA PLC Price
ASTRAZENECA PLC Price | ASTRAZENECA PLC Quote
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>